{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:10:47Z","timestamp":1694812247026},"reference-count":0,"publisher":"National Library of Serbia","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med pregl","MED PREGLED"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>Introduction. Seroprevlence of chronic hepatitis C viral infection in\n   correctional facilities ranges from 16% to 49%. However, there are only very\n   limited data available on the course of hepatitis C viral infection and\n   outcomes of treatment with pegylated interferon plus ribavirin in\n   correctional settings. The aim of this study was to assess the feasibility\n   and effectiveness of use of pegylated interferon plus ribavirin treatment in\n   the Serbian correctional setting. Material and Methods. The study sample\n   consisted of the patients with hepatitis C hospitalized in the Special\n   Hospital for Prisoners in Belgrade (Serbia) during 2007-2013. Health\n   authorities approved treatment for 32 patients out of 76 treatment-naive\n   patients referred to this institution. The patients (N=32) received 180 mcg\n   pegylated interferon alfa-2a once a week plus oral ribavirin in dosage of\n   800mg or 1000\/1200 mg\/day for 24 or 48-week treatment. All patients who\n   completed therapy were assessed at the end of an additional 24-week\n   treatment-free period for a sustained virological response. Results.\n   Sustained virological response was achieved in 53.8% of hepatitis C viral\n   infection genotype 1 patients and in 73.3% and 66.6% of patients with\n   hepatitis C viral infection genotype 3 and 4, respectively. One patient with\n   mixed genotype (1, 2) did not achieve sustained virological response. The\n   overall safety profile of the treatment regimen was very good. The incidence\n   of influenza-like symptoms and depression were low. A serious adverse event\n   was recorded only in 6.4% of patients. Conclusion. The results showed that\n   pegylated interferon alfa-2a plus ribavirin given once a week was well\n   tolerated among prisoners and the regimen had the same adherence and\n   effectiveness as in general population.<\/jats:p>","DOI":"10.2298\/mpns1604085s","type":"journal-article","created":{"date-parts":[[2016,4,15]],"date-time":"2016-04-15T13:38:03Z","timestamp":1460727483000},"page":"85-91","source":"Crossref","is-referenced-by-count":3,"title":["Antiviral treatment of hepatitis C in Serbian prison setting: Medical treatment outcomes and patients\u2019 adherence"],"prefix":"10.2298","volume":"69","author":[{"given":"Jasmina","family":"Simonovic-Babic","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Belgrade + Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenija","family":"Bojovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade + Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Delic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade + Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Katanic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Mitrovic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Malinic","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia, Department of Infectious and Tropical Diseases, Belgrade"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1078","container-title":["Medicinski pregled","Medical review"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T09:25:21Z","timestamp":1685352321000},"score":1,"resource":{"primary":{"URL":"https:\/\/doiserbia.nb.rs\/Article.aspx?ID=0025-81051604085S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":0,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2298\/mpns1604085s","relation":{},"ISSN":["0025-8105","1820-7383"],"issn-type":[{"value":"0025-8105","type":"print"},{"value":"1820-7383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}